OHR Pharmaceutical (NASDAQ:OHRP) announced its earnings results on Wednesday. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.07), Bloomberg Earnings reports.
Shares of OHR Pharmaceutical (NASDAQ:OHRP) opened at $0.31 on Thursday. OHR Pharmaceutical has a 52 week low of $0.27 and a 52 week high of $2.18.
Several equities research analysts have weighed in on OHRP shares. Roth Capital started coverage on shares of OHR Pharmaceutical in a research note on Monday, November 27th. They issued a “buy” rating and a $7.00 price target for the company. ValuEngine downgraded shares of OHR Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Friday, January 5th. Finally, Zacks Investment Research raised shares of OHR Pharmaceutical from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research note on Wednesday, October 25th.
COPYRIGHT VIOLATION NOTICE: “OHR Pharmaceutical (OHRP) Announces Earnings Results, Meets Estimates” was published by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/02/15/ohr-pharmaceutical-ohrp-announces-earnings-results-meets-estimates.html.
About OHR Pharmaceutical
OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
Receive News & Ratings for OHR Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OHR Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.